DBV Technologies: Funding, Investors & Team (Sep 2026)
DBV Technologies is a worldwide clinical stage biopharmaceutical organization established by pediatricians and business visionaries who accepted that food sensitivities might one day at some point be dealt with securely and really. With this mission driving their obligation to the progression of medicines in this field, they are researching a possible new class of immunotherapy that expects to enact the resistant arrangement of patients through the skin.
DBV Technologies has raised $222M across 2 funding rounds on record, the most recent an undisclosed round of $30.0M announced in Oct 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
DBV Technologies Company Profile and Key Stats
Latest funding round on record: Oct 2025.
DBV Technologies Funding Rounds
DBV Technologies raised $192M in a Post-IPO Equity announced in Jun 2022.
3.3 years later, an undisclosed round of $30.0M was announced in Oct 2025.
DBV Technologies Founders and Leadership Team
Contact details for the DBV Technologies team: 1 of 2 have an email address on file.
Start 14-day free trial →DBV Technologies Funding Compared to Other Biotechnology Startups
DBV Technologies' latest round of $30.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like DBV Technologies in Biotechnology and Bagneux
Companies Similar to DBV Technologies
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
DBV Technologies Funding FAQs
What does DBV Technologies do?
DBV Technologies is a worldwide clinical stage biopharmaceutical organization established by pediatricians and business visionaries who accepted that food sensitivities might one day at some point be dealt with securely and really. With this mission driving their obligation to the progression of medicines in this field, they are researching a possible new class of immunotherapy that expects to enact the resistant arrangement of patients through the skin.
How much funding has DBV Technologies raised?
DBV Technologies has raised $222M across 2 rounds on record. The most recent is an undisclosed round of $30.0M announced in Oct 2025.
When did DBV Technologies last raise funding?
DBV Technologies' most recent funding round on record is an undisclosed round of $30.0M, announced in Oct 2025.
Who founded DBV Technologies?
FundedIQ lists Pierre Benhamou (Founder) at DBV Technologies.
Who is the CEO of DBV Technologies?
Daniel Tasse is listed as CEO at DBV Technologies.
Where is DBV Technologies headquartered?
DBV Technologies is based in Bagneux, Ile-De-France, France.
How many employees does DBV Technologies have?
DBV Technologies is in the 101-250 employee band.
How does DBV Technologies' funding compare to other Biotechnology startups?
DBV Technologies' latest round of $30.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's DBV Technologies Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for DBV Technologies is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.